To the Editor: Redfield et al. (June 13 issue)1 reported the initial results of a phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with human immunodeficiency virus (HIV) infection. They concluded that gp160 vaccine is safe on the basis of in vitro mitogen-driven and antigen-specific proliferative responses of lymphocytes (although the actual data were not shown). We would like to advocate a high level of caution about the vaccine strategy that uses HIV envelope proteins gp120 and gp160. On the basis of intensive studies in our laboratory and others, the immunosuppressive effects of. . .
ASJC Scopus subject areas